Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: evidence from a systematic literature review
Indirect comparison of efficacy of zanubrutinib versus acalabrutinib in the treatment of relapsed/refractory mantle cell lymphoma
Zanubrutinib vs. acalabrutinib in B-cell malignancies: An adverse event-based economic analysis
Zanubrutinib (zanu) versus acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based economic analysis
Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascualr disease: evidence from a systematic literature review and feasibility assessment for meta-analysis
Characteristics and lipid lowering treatment patterns in patients with lipoprotein(a) test: a real-world US study
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)

A systematic literature review (SLR) of real-world studies of advanced therapies in moderate-to-severe ulcerative colitis (UC): study, patient and clinical characteristics, and outcomes

Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review

From Submission to Reimbursement: Navigating the COVID-19 Ripple Effect on Therapy Access in Canada
